Vital Therapies Trading Up 9.1% on Analyst Upgrade (VTL)
Vital Therapies (NYSE:VTL)’s share price traded up 9.1% on Monday after William Blair raised their price target on the stock to $36.00, Analyst Ratings Network.com reports. The stock traded as high as $27.10 and last traded at $25.65, with a volume of 81,264 shares changing hands. The stock had previously closed at $23.52.
A number of other firms have also recently commented on VTL. Analysts at Bank of America initiated coverage on shares of Vital Therapies in a research note on Monday, May 12th. They set a “buy” rating on the stock. Separately, analysts at Canaccord Genuity initiated coverage on shares of Vital Therapies in a research note on Monday, May 12th. They set a “buy” rating and a $20.00 price target on the stock. Finally, analysts at Credit Suisse initiated coverage on shares of Vital Therapies in a research note on Monday, May 12th. They set an “outperform” rating and a $16.00 price target on the stock.
The stock has a 50-day moving average of $23.19 and a 200-day moving average of $18.57. The company’s market cap is $541.6 million.
Vital Therapies (NYSE:VTL) last released its earnings data on Tuesday, June 3rd. The company reported ($24.49) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.54) by $23.95. On average, analysts predict that Vital Therapies will post $-2.47 earnings per share for the current fiscal year.
Vital Therapies, Inc is a biotherapeutic company. The Company focused on developing a cell-based therapy targeting the treatment of all forms of acute liver failure.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.